These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31902692)

  • 1. Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France.
    Olivereau L; Nave V; Garcia S; Perceval M; Rabilloud M; Durieu I; Reynaud Q
    J Cyst Fibros; 2020 May; 19(3):402-406. PubMed ID: 31902692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
    McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
    Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
    Moheet A; Beisang D; Zhang L; Sagel SD; VanDalfsen JM; Heltshe SL; Frederick C; Mann M; Antos N; Billings J; Rowe SM; Moran A;
    J Cyst Fibros; 2021 Mar; 20(2):333-338. PubMed ID: 32917547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
    Ejiofor LCK; Mathiesen IHM; Jensen-Fangel S; Olesen HV; Skov M; Philipsen LKD; Pedersen CL; Pressler T
    Pediatr Pulmonol; 2020 Dec; 55(12):3364-3370. PubMed ID: 32897653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
    Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
    J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
    Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
    Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR.
    Taylor-Cousar JL; Jain M; Barto TL; Haddad T; Atkinson J; Tian S; Tang R; Marigowda G; Waltz D; Pilewski J;
    J Cyst Fibros; 2018 Mar; 17(2):228-235. PubMed ID: 29126871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
    Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
    Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
    Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG
    J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
    Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor/ivacaftor: an assessment using linked registry data in Sweden.
    Lindblad A; Monestrol I; Gilljam M; Krantz C; McGarry LJ; Banefelt J; Aldvén M
    J Med Econ; 2024; 27(1):897-906. PubMed ID: 38939921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 15. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
    Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG
    Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.
    Dilokthornsakul P; Patidar M; Campbell JD
    Value Health; 2017 Dec; 20(10):1329-1335. PubMed ID: 29241892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
    Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
    Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
    Casciaro R; Costa S; Dang P; Majo F; Ros M
    Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146
    [No Abstract]   [Full Text] [Related]  

  • 19. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
    Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
    Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.
    Burgel PR; Munck A; Durieu I; Chiron R; Mely L; Prevotat A; Murris-Espin M; Porzio M; Abely M; Reix P; Marguet C; Macey J; Sermet-Gaudelus I; Corvol H; Bui S; Lemonnier L; Dehillotte C; Da Silva J; Paillasseur JL; Hubert D;
    Am J Respir Crit Care Med; 2020 Jan; 201(2):188-197. PubMed ID: 31601120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.